BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29770473)

  • 21. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
    Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
    Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
    Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways.
    Li L; Li Y; Zou H
    PeerJ; 2021; 9():e12356. PubMed ID: 34760374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
    Mu Y; Sun D
    Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
    Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
    Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
    Gao Z; Chen W; Zhang X; Cai P; Fang X; Xu Q; Sun Y; Gu Y
    Biomed Pharmacother; 2013 Jun; 67(5):351-6. PubMed ID: 23602321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression.
    Sun J; Jiang W; Tian D; Guo Q; Shen Z
    Onco Targets Ther; 2018; 11():8227-8237. PubMed ID: 30538492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.
    Zheng Y; Fang W; Deng J; Zhao P; Xu N; Zhou J
    J Thorac Dis; 2014 Jul; 6(7):958-64. PubMed ID: 25093093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK.
    Zhao G; Feng L; Ye T; Liu Y; Fan L; Ye C; Chen J
    Thorac Cancer; 2023 Aug; 14(22):2127-2138. PubMed ID: 37337933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
    Yang G; Yao Y; Zhou J; Zhao Q
    Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
    Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capilliposide C from
    Wu K; Chen X; Feng J; Zhang S; Xu Y; Zhang J; Wu Q; You M; Xia B; Ma S
    Front Oncol; 2021; 11():644117. PubMed ID: 33869036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
    Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
    Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
    Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Kimple RJ; Vaseva AV; Cox AD; Baerman KM; Calvo BF; Tepper JE; Shields JM; Sartor CI
    Clin Cancer Res; 2010 Feb; 16(3):912-23. PubMed ID: 20103665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
    Chen P; Dai CH; Shi ZH; Wang Y; Wu JN; Chen K; Su JY; Li J
    Apoptosis; 2021 Dec; 26(11-12):639-656. PubMed ID: 34743246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Xue ZX; Wen WX; Zhuang Y; Hua ZJ; Xia YN
    Mol Clin Oncol; 2016 Sep; 5(3):265-268. PubMed ID: 27588191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.